Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations
- 10 August 2006
- journal article
- Published by Elsevier in Microbes and Infection
- Vol. 8 (11) , 2599-2604
- https://doi.org/10.1016/j.micinf.2006.07.011
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellersJournal of Antimicrobial Chemotherapy, 2005
- Cytochrome b Mutations That Modify the Ubiquinol-binding Pocket of the Cytochrome bc1 Complex and Confer Anti-malarial Drug Resistance in Saccharomyces cerevisiaeJournal of Biological Chemistry, 2005
- Multiple Cytochrome b Mutations May Cause Atovaquone ResistanceThe Journal of Infectious Diseases, 2005
- Screening for Mutations Related to Atovaquone/Proguanil Resistance in Treatment Failures and Other Imported Isolates ofPlasmodium falciparumin EuropeThe Journal of Infectious Diseases, 2004
- Plasmodium falciparumClonal Population Dynamics during Malaria TreatmentThe Journal of Infectious Diseases, 2004
- Structure of the Yeast Cytochrome bc 1 Complex with a Hydroxyquinone Anion Qo Site Inhibitor BoundJournal of Biological Chemistry, 2003
- Genetic Confirmation of Atovaquone-Proguanil-Resistant Plasmodium falciparum Malaria Acquired by a Nonimmune Traveler to East AfricaClinical Infectious Diseases, 2003
- Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reportsBMJ, 2003
- Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum*Clinical Pharmacology & Therapeutics, 1997
- Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3- hydroxy-1,4-naphthoquinone (566C80)Biochemical Pharmacology, 1992